134 related articles for article (PubMed ID: 9177268)
1. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.
Wang P; Myers JG; Wu P; Cheewatrakoolpong B; Egan RW; Billah MM
Biochem Biophys Res Commun; 1997 May; 234(2):320-4. PubMed ID: 9177268
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase.
Fisher DA; Smith JF; Pillar JS; St Denis SH; Cheng JB
Biochem Biophys Res Commun; 1998 May; 246(3):570-7. PubMed ID: 9618252
[TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
4. TcPDE4, a novel membrane-associated cAMP-specific phosphodiesterase from Trypanosoma cruzi.
Alonso GD; Schoijet AC; Torres HN; Flawiá MM
Mol Biochem Parasitol; 2006 Jan; 145(1):40-9. PubMed ID: 16225937
[TBL] [Abstract][Full Text] [Related]
5. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
6. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
Foissier L; Lonchampt M; Cogé F; Canet E
J Pharmacol Exp Ther; 1996 Sep; 278(3):1484-90. PubMed ID: 8819536
[TBL] [Abstract][Full Text] [Related]
7. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
11. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
[TBL] [Abstract][Full Text] [Related]
12. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
[TBL] [Abstract][Full Text] [Related]
13. Characterization of two human cAMP-specific phosphodiesterase subtypes expressed in baculovirus-infected insect cells.
Amegadzie BY; Hanning CR; McLaughlin MM; Burman M; Cieslinski LB; Livi GP; Torphy TJ
Cell Biol Int; 1995 Jun; 19(6):477-84. PubMed ID: 7640661
[TBL] [Abstract][Full Text] [Related]
14. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
15. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells.
Leroy MJ; Degerman E; Taira M; Murata T; Wang LH; Movsesian MA; Meacci E; Manganiello VC
Biochemistry; 1996 Aug; 35(31):10194-202. PubMed ID: 8756484
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
17. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells.
Jiang X; Li J; Paskind M; Epstein PM
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):11236-41. PubMed ID: 8855339
[TBL] [Abstract][Full Text] [Related]
19. Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
Lagente V; Hichami A; Boichot E; Martins MA; Silva PM
Allerg Immunol (Paris); 1995 Feb; 27(2):34-9. PubMed ID: 7710653
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
J Pharmacol Exp Ther; 1997 Jul; 282(1):505-12. PubMed ID: 9223593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
